REASSURE: The Effect of Rimonabant on HbA1c in Overweight or Obese Patients With Type 2 Diabetes Not Adequately Controlled on 2 Oral Antidiabetic Agents

PHASE3CompletedINTERVENTIONAL

Enrollment

358

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Rimonabant

White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast

DRUG

Placebo

Matching placebo tablets. Once daily before breakfast

Trial Locations (1)

Sanofi-Aventis Administrative Office, North Ryde